Trial Profile
A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Fitusiran (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals; Sanofi
- 12 Dec 2023 Resultsof pooled analysis from Phase 1 (NCT02035605), Phase 1/2 (NCT02554773) and Phase 3 studies (NCT03417102, NCT03417245, NCT03549871) in PwH A/B, with or without inhibitors, PopPK/PD model, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Feb 2021 Results of part D (n=17 male) evaluating the safety and efficacy of fitusiran treatment for people with moderate/severe hemophilia A or B with inhibitors, published in the Journal of Thrombosis and Haemostasis
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology